Table 3.
Univariate analysis of risk factors for post-ERCP pancreatitis in patients with and without pancreatitis
| Non-pancreatitis group, n (%) | Pancreatitis group, n (%) | Total (n = 704) n (%) | p value | |
|---|---|---|---|---|
| PD dilation | 8 (100) | 0 (0) | 8 (100) | 0.739 |
| Suspected SOD | 8 (100) | 0 (0) | 8 (100) | 0.739 |
| Cholecystectomy | 37 (97.4) | 1 (2.6) | 38 (100) | 0.581 |
| CBD stone | 80 (97.6) | 2 (2.4) | 82 (100) | 0.355 |
| Difficult cannulation | 130 (95.6) | 6 (4.4) | 136 (100) | 0.343 |
| Sphincterotomy | 150 (97.4) | 4 (2.6) | 154 (100) | 0.134 |
| Needle knife precut | 23 (100) | 0 (0.0) | 23 (100) | 0.403 |
| PD cannulation | 11 (91.7) | 1 (8.3) | 12 (100) | 0.368 |
| PD injection | 6 (100) | 0 (0) | 6 (100) | 0.798 |
| Balloon dilation of sphincter of Oddi | 36 (94.7) | 2 (5.3) | 38 (100) | 0.419 |
| CBD dialation | 123 (95.4) | 5 (4.6) | 128 (100) | 0.571 |
| Biliary stricture | 30 (93.8) | 2 (6.2) | 32 (100) | 0.330 |
| Biliary duct tumor | 15 (93.8) | 1 (6.2) | 14 (100) | 0.462 |
| Peri-ampullary diverticulum | 47 (95.9) | 2 (4.1) | 49 (100) | 0.571 |
| Medication | ||||
| Epinephrine | 66 (100) | 0 (0.0) | 66 (100) | 0.016 |
| Indomethacin | 62 (91.2) | 6 (8.8) | 68 (100) | |
| Combination | 57 (98.3) | 1 (1.7) | 58 (100) | |
ERCP, endoscopic retrograde cholangiopancreatography; PD, pancreatic duct; CBD, common bile duct; SOD, sphincter of Oddi dysfunction.